“Fasting kills cancer and this has been proven by science." (Instagram Reel, @dryahiaanane, published 2025-03-29. Supporting video text includes: "cancer cells cannot survive without Glucose," fasting "increases ketones Which cancer cells cannot metabolize effectively," and an offer of a "cancer cure protocol" in exchange for a comment.)”

The strongest human evidence does not show that fasting kills cancer. The DIRECT trial, the most-cited randomized trial in this area, enrolled 131 patients with HER2-negative stage II/III breast cancer and randomized them to a fasting-mimicking diet or regular diet for three days before and during neoadjuvant chemotherapy. Its reported findings were that there was no difference in toxicity between groups despite dexamethasone being omitted in the fasting group, and that the diet appeared to enhance the effect of chemotherapy on radiological and pathological response. The authors framed this as encouraging further exploration, not as a demonstrated treatment. It is a phase 2 trial using surrogate response endpoints, not a survival trial, and fasting was tested only alongside chemotherapy, never instead of it. A 2025 systematic review of intermittent fasting in cancer patients receiving chemotherapy or targeted therapy screened 1,725 articles and included nine studies covering 354 patients, the majority with breast cancer. It concluded that intermittent fasting was safe and feasible, but that no impact on treatment outcomes or chemotherapy-related toxicities was demonstrated. The only consistent signals were biomarker changes: reduced insulin and IGF-1, plus increased erythrocyte levels. The authors stated that robust evidence is lacking for a definitive conclusion. A 2025 Cureus review published on the same date as this reel asked directly whether fasting is a cancer treatment or a myth. It concluded there is insufficient evidence to support fasting as a primary treatment, and that fasting remains a complementary approach rather than a standalone solution in oncology. The American Cancer Society position, as quoted in secondary compilation, is that available scientific evidence does not support claims that fasting is effective for preventing or treating cancer in humans, with similar conclusions reached by professional bodies in France and the UK. On the mechanistic premises: Cancer Research UK explains that the "starve cancer of sugar" idea originates in the Warburg effect, but that all healthy cells also require glucose and there is no way to direct the body to withhold glucose from tumour cells while supplying normal ones. The Canadian Cancer Society states plainly that eating sugar does not make cancer cells grow faster and that all cells require glucose. The World Cancer Research Fund describes the Warburg effect as a preferential shift toward glycolysis, not an absolute dependence. On the ketone premise: preclinical work shows the opposite of the claim in at least some tumour types. Pancreatic ductal adenocarcinoma cells were reported to adapt to ketogenic conditions by shifting from glycolysis to mitochondrial metabolism, efficiently metabolizing ketone bodies, fatty acids and especially glutamine to sustain TCA cycle activity. Ketone body metabolism in tumours is an active research area precisely because tumour cells can engage with it, with effects varying by cancer type. On safety: a peer-reviewed commentary notes that guidelines on nutritional support in cancer patients state fasting before or during chemotherapy is not recommended, particularly in malnourished patients or those at nutritional risk, citing risks of malnutrition and sarcopenia, and the further risk that patients may extend fasting and chronically reduce calorie intake. The same source identifies disinformation about anti-cancer diets as a distinct hazard.